Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Organisation › Details

Abingworth Bioventures 8 (ABV 8)

Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in 170 life science companies, leading to 44 M&As and 69 IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. *

 

Period Start 2021-02-03 closing, final
  Group Abingworth (Group)
Products Industry Abingworth Bioventures 8 (ABV 8)
  Industry 2 LIFE SCIENCES
Persons Person Haines, Timothy (Tim) (Abingworth 201507– Managing Partner joined 2005 before Astex CEO)
  Person 2 von Emster, Kurt (Abingworth 201507– Managing Partner joined 201501 before venBio + MPM Capital + Franklin Templeton)
     
Region Region London, Greater London
  Country United Kingdom (GB)
  City n. a. London
    Address record changed: 2021-02-04
     
Basic data Employees n. a.
     
    * Document for �About Section�: Abingworth LLP. (2/3/21). "Press Release: Abingworth Raises $465m for New Life Sciences Fund Abingworth Bioventures 8". London.
     
   
Record changed: 2021-05-21

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Abingworth (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80




» top